Study Metrics
Total Sample
121
Treatment Group
82
Control Group
39
Covariates
11
PICO Comparisons
1
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Evans |
| Publication Year: | 2023 |
| DOI: | https://doi.org/10.1371/journal.pone.0268807 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | University of Bristol, North Bristol NHS Trust |
| Funding: | Declared: Public, NGO |
| Funding Institutions: | This National Institute for Health Research (NIHR) Programme Grants for Applied Research funded the BSI-FOO and RAPIDO studies (RP-PG-0707-10043). The British Heart Foundation and NIHR Bristol Biomedical Research Unit for Cardiovascular Disease and North Bristol Charitable Funds funded some staff time (JH, CR, RE). |
Study Context
| Disease: | Blood infection |
| Disease Category: | Hematology |
| Data Type: | Other |
| Number of Data Sources: | 1 |
| Geography: | UK |
| Eligible Sample: | 163.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Missing Data Method: | Conditional mean imputation |
| Matching Method: | PS matching |
| Analysis Method: | Logistic regression |
| Estimand: | PP |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | MERINO |
| Registration Number: | NCT02176122 |
| Target Trial DOI: | https://doi.org/10.1001/jama.2018.12163 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
all-cause mortality at 25 days
MERINO
OR
Efficacy
Population
Patients with bloodstream infection with E. colior Klebsiella spp. with proven non-susceptibility to third generation cephalosporins and susceptibility to meropenem and piperacillin- tazobactam
Intervention
Piperacillin-tazobactam 4.5g administered every 6 hours intravenously
Comparison
Meropenem 1g administered every 8 hours intravenously
Outcome
all-cause mortality at 25 days
RCT Result
3.69
95% CI: [1.48, 10.40]
vs
TTE Result
1.31
95% CI: [0.40, 4.26]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Transparency Indicators
Protocol Registration
Available
Data Sharing
Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: None |
| Funding Source: | Declared: Public, NGO |
| Funding Institutions: | This National Institute for Health Research (NIHR) Programme Grants for Applied Research funded the BSI-FOO and RAPIDO studies (RP-PG-0707-10043). The British Heart Foundation and NIHR Bristol Biomedical Research Unit for Cardiovascular Disease and North Bristol Charitable Funds funded some staff time (JH, CR, RE). |